Camac Fund, LP, Insider at Pasithea Therapeutics Corp. (KTTA), bought 122,004 shares at $1.19 ($145K) on 2022-09-28, disclosed to the SEC on 2022-09-30.
Open-market purchase of $145k KTTA by Insider. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $1.19 | 57,647 | $69K | 47.3% |
| 2 | $1.19 | 57,647 | $69K | 47.3% |
| 3 | $1.16 | 6,710 | $8K | 5.4% |
| Total | $1.19 avg | 122,004 | $145K | 100% |
| Filing → |
| ABCP | SELL | 2024-02-20 | $1.4M | — | Filing → |
| ABCP | SELL | 2023-10-11 | $8K | — | Filing → |
| ABCP | SELL | 2023-09-26 | $11K | — | Filing → |